Jane Street’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.94M | Buy |
994,413
+449,377
| +82% | +$4.06M | ﹤0.01% | 2831 |
|
|
2026
Q1 | $5.19M | Buy |
545,036
+4,936
| +0.9% | +$38.3K | ﹤0.01% | 3458 |
|
|
2025
Q4 | $4.21M | Buy |
540,100
+6,200
| +1% | +$44.8K | ﹤0.01% | 3503 |
|
|
2025
Q3 | $4.05M | Sell |
533,900
-123,600
| -19% | -$1.03M | ﹤0.01% | 3730 |
|
|
2025
Q2 | $5.89M | Buy |
657,500
+126,000
| +24% | +$1.17M | ﹤0.01% | 2788 |
|
|
2025
Q1 | $3.99M | Buy |
531,500
+455,000
| +595% | +$3.67M | ﹤0.01% | 3270 |
|
|
2024
Q4 | $575K | Sell |
76,500
-12,200
| -14% | -$92.6K | ﹤0.01% | 6497 |
|
|
2024
Q3 | $674K | Sell |
88,700
-1,900
| -2% | -$14.4K | ﹤0.01% | 6655 |
|
|
2024
Q2 | $560K | Buy |
90,600
+14,700
| +19% | +$81.1K | ﹤0.01% | 6838 |
|
|
2024
Q1 | $386K | Sell |
75,900
-213,300
| -74% | -$1.2M | ﹤0.01% | 7147 |
|
|
2023
Q4 | $1.73M | Sell |
289,200
-8,800
| -3% | -$51K | ﹤0.01% | 4587 |
|
|
2023
Q3 | $2.11M | Buy |
298,000
+139,200
| +88% | +$1M | ﹤0.01% | 3972 |
|
|
2023
Q2 | $1.12M | Sell |
158,800
-28,200
| -15% | -$226K | ﹤0.01% | 5033 |
|
|
2023
Q1 | $1.56M | Sell |
187,000
-203,100
| -52% | -$1.96M | ﹤0.01% | 4238 |
|
|
2022
Q4 | $4.48M | Sell |
390,100
-217,700
| -36% | -$2.71M | ﹤0.01% | 2646 |
|
|
2022
Q3 | $7.66M | Buy |
607,800
+67,400
| +12% | +$867K | ﹤0.01% | 2008 |
|
|
2022
Q2 | $5.72M | Sell |
540,400
-213,300
| -28% | -$2.2M | ﹤0.01% | 2470 |
|
|
2022
Q1 | $12.3M | Buy |
753,700
+235,100
| +45% | +$3.77M | ﹤0.01% | 1737 |
|
|
2021
Q4 | $7.18M | Sell |
518,600
-132,600
| -20% | -$1.75M | ﹤0.01% | 2320 |
|
|
2021
Q3 | $9.36M | Buy |
651,200
+73,600
| +13% | +$1.16M | ﹤0.01% | 1879 |
|
|
2021
Q2 | $9.13M | Sell |
577,600
-65,100
| -10% | -$885K | ﹤0.01% | 1836 |
|
|
2021
Q1 | $6.54M | Buy |
642,700
+291,000
| +83% | +$3M | ﹤0.01% | 2033 |
|
|
2020
Q4 | $2.62M | Buy |
351,700
+211,200
| +150% | +$1.09M | ﹤0.01% | 3042 |
|
|
2020
Q3 | $483K | Sell |
140,500
-122,400
| -47% | -$525K | ﹤0.01% | 5204 |
|
|
2020
Q2 | $1.25M | Buy |
+262,900
| New | +$1.05M | ﹤0.01% | 3740 |
|
|
2017
Q3 | – | Sell |
-85,700
| Closed | -$476K | – | 4435 |
|
|
2017
Q2 | $476K | Buy |
85,700
+72,700
| +559% | +$443K | ﹤0.01% | 3093 |
|
|
2017
Q1 | $109K | Buy |
13,000
+2,300
| +21% | +$16K | ﹤0.01% | 3963 |
|
|
2016
Q4 | $68K | Buy |
+10,700
| New | +$55.7K | ﹤0.01% | 3913 |
|
|
2015
Q4 | – | Sell |
-17,100
| Closed | -$195K | – | 3981 |
|
|
2015
Q3 | $195K | Buy |
+17,100
| New | +$228K | ﹤0.01% | 3200 |
|
Other funds holding BCRX
RCM
DM
TCM
PA
JT
VPC
Jane Street's BCRX Position: Q2 2026 in Review
Jane Street increased its BioCryst Pharmaceuticals (BCRX) stake by 344% in Q2 2026, buying an estimated $19.4M and bringing the position to 2,762,683 shares worth $27.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1859.
Jane Street first reported a position in BCRX in Q2 2013 and has held it in 37 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.
- Jane Street held 2,762,683 shares of BioCryst Pharmaceuticals worth $27.6M as of Q2 2026.
- Jane Street bought 2,140,076 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $19.4M.
- BioCryst Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #1859 holding.
- Jane Street first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
- 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.